Attempts to reclassify injectable B12 to a Pharmacy (P) or General Sales List (GSL) medicine have consistently met resistance from the Medicines and Healthcare products Regulatory Agency and the government, based on two key legal criteria outlined in the Human Medicines Regulations 2012 : 1
This is consistent with the fact that this class of drugs produces significant appetite suppression in response to central and peripheral GLP-1 R activation and has been actively used in the treatment of T2DM, obesity, and overweight ( Our study identified a potential risk of dehydration with dulaglutide, liraglutide, semaglutide, and tirzepatide, semaglutide emerged as having the highest risk of various fluid reductions (Supplementary Table S2)
Eat smaller, more frequent meals rather than large ones
L-carnitine can help increase fat metabolism but will not produce significant weight loss on its own
Glutamine mimicry suppresses tumor progression through asparagine metabolism in pancreatic ductal adenocarcinoma
These injections are commonly used to boost energy levels, improve health, and address vitamin B12 deficiencies
